<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age/><report-id>PHHY2012FR113182</report-id><gender>male</gender><reactions><reaction>Electrocardiogram deflection/ Signs of an asymptomatic previous cardiac event on electrocardiogram</reaction><reaction>Subclinical myocardial infarction</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>TASIGNA</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053130_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133930</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012FR113182</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR113182</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>PHHO2008FR05568</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>PHHO2008FR05280</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Retinal vein occlusion</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>19980211</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Thrombophlebitis superficial</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200710</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Intermittent claudication</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200710</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Peripheral artery stenosis</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200710</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Peripheral arterial occlusive disease</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Femoral artery occlusion</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Peripheral artery stenosis</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20071213</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Stent placement</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20080111</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tachycardia</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200801</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tachycardia</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200802</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Stent placement</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Vascular graft</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Carotid artery restenosis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Peripheral artery bypass</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201109</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Overweight</patientepisodename>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>GLIVEC</patientdrugname>
				<patientdrugstartdateformat>102</patientdrugstartdateformat>
				<patientdrugstartdate>20010518</patientdrugstartdate>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>HYDREA</patientdrugname>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>ROFERON</patientdrugname>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>ATENOLOL</patientdrugname>
				<patientindicationmeddraversion>15.1</patientindicationmeddraversion>
				<patientdrugindication>10043071</patientdrugindication>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Electrocardiogram deflection/ Signs of an asymptomatic previous cardiac event on electrocardiogram</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Electrocardiogram abnormal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Electrocardiogram abnormal</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Subclinical myocardial infarction</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Myocardial infarction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myocardial infarction</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2006-10-10</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2008-02-19</drugenddate>
				<drugtreatmentduration>498</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2008-04-10</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-10-21</drugenddate>
				<drugtreatmentduration>925</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>TASIGNA</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>200 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-10-21</drugstartdate>
				<drugenddateformat>610</drugenddateformat>
				<drugenddate>2012-11-01</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Electrocardiogram abnormal</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR113182, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>received on 05 Dec 2012. This report refers to a male patient of unspecified age. The patient had no medical history of <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">type <Semaphore x="2659346" class="Disease or Finding" value="Type 1 Diabetes Mellitus" score="1.00" ID="C2986">1 or <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">type 2 <Semaphore x="2904422" class="MedDRA LLT" value="Diabetes mellitus" score="1.00" ID="10012601">diabetes</Semaphore></Semaphore></Semaphore>
     <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">, </Semaphore></Semaphore><Semaphore x="2036179" class="Disease or Finding" value="Hypercholesterolemia" score="1.00" ID="C37967">hypercholesterolemia</Semaphore>, <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, <Semaphore x="2940276" class="MedDRA LLT" value="Exercise lack of" score="1.00" ID="10015650">sedentary</Semaphore>, alcohol consumption, <Semaphore x="2038450" class="Disease or Finding" value="Hyperthyroidism" score="1.00" ID="C3123">hyperthyroidism</Semaphore>, transient ischemic accident/cerebrovascular <Semaphore x="1411837" class="Disease or Finding" value="Accident" score="1.00" ID="C34340">accident </Semaphore>and <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>use. The patient medical history included pre <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="673983" class="Medicine" value="Hydrea" score="0.49" ID="239551">Hydrea </Semaphore>(<Semaphore x="687729" class="Medicine" value="hydroxyurea" score="0.49" ID="270940">hydroxyurea</Semaphore>), Roferon (<Semaphore x="735567" class="Medicine" value="Interferon-alpha" score="0.74" ID="270116">interferon alpha</Semaphore>) and Glivec (<Semaphore x="699336" class="Medicine" value="imatinib" score="0.49" ID="252378">imatinib</Semaphore>)<Semaphore x="2465418" class="AnatomicStructure" value="Retina Layer" score="1.00" ID="C49328">, left <Semaphore x="1917161" class="AnatomicStructure" value="Eye" score="1.00" ID="C12401">eye </Semaphore><Semaphore x="1130515" class="Medicine" value="Retin-A" score="0.49" ID="239679">retina </Semaphore><Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="0.58" ID="C12814"><Semaphore x="1743448" class="AnatomicStructure" value="Central Vein" score="1.00" ID="C32281">central <Semaphore x="2593269" class="AnatomicStructure" value="Superficial Vein" score="1.00" ID="C33666">vein </Semaphore></Semaphore>
      <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="0.58" ID="C12814">
       <Semaphore x="1930211" class="Disease or Finding" value="Femoropopliteal Occlusive Disease" score="1.00" ID="C35793">
        <Semaphore x="1930182" class="AnatomicStructure" value="Femoral Vein" score="1.00" ID="C12716">
         <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="0.58" ID="C12814">
          </Semaphore>
         <Semaphore x="2593269" class="AnatomicStructure" value="Superficial Vein" score="1.00" ID="C33666"><Semaphore x="1841229" class="Disease or Finding" value="Dental Occlusion" score="1.00" ID="C62301">occlusion</Semaphore>, </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="0.58" ID="C12814">
     <Semaphore x="2684055" class="AnatomicStructure" value="Vein" score="0.58" ID="C12814">
      <Semaphore x="1930211" class="Disease or Finding" value="Femoropopliteal Occlusive Disease" score="1.00" ID="C35793">
       <Semaphore x="1930182" class="AnatomicStructure" value="Femoral Vein" score="1.00" ID="C12716">
        <Semaphore x="2593269" class="AnatomicStructure" value="Superficial Vein" score="1.00" ID="C33666">superficial </Semaphore></Semaphore></Semaphore></Semaphore>
     <Semaphore x="1930211" class="Disease or Finding" value="Femoropopliteal Occlusive Disease" score="1.00" ID="C35793">
      <Semaphore x="1930182" class="AnatomicStructure" value="Femoral Vein" score="1.00" ID="C12716">femoral </Semaphore></Semaphore></Semaphore><Semaphore x="2614723" class="Disease or Finding" value="Thrombosis" score="1.00" ID="C26891">thrombosis</Semaphore>, left sural <Semaphore x="1784370" class="Disease or Finding" value="Claudication" score="1.00" ID="C50495">claudication </Semaphore>with progression and diminution of perimeter of <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.58" ID="C91103">walk</Semaphore>, <Semaphore x="2584843" class="Disease or Finding" value="Stenosis" score="1.00" ID="C50754">stenosis </Semaphore>of the left <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372"><Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">femoral artery</Semaphore>, </Semaphore><Semaphore x="3180042" class="MedDRA LLT" value="Peripheral arterial occlusive disease" score="1.00" ID="10062585">peripheral <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">artery </Semaphore><Semaphore x="2329336" class="Disease or Finding" value="Occlusion" score="1.00" ID="C50678">occlusive </Semaphore>disease </Semaphore>with <Semaphore x="2614723" class="Disease or Finding" value="Thrombosis" score="1.00" ID="C26891">thrombosis </Semaphore>of left <Semaphore x="1929962" class="AnatomicStructure" value="Femoral Artery Branch" score="1.00" ID="C32592">superficial femoral artery </Semaphore>in aductor <Semaphore x="1672327" class="AnatomicStructure" value="Canal" score="1.00" ID="C61487">canal </Semaphore>(Hunter's <Semaphore x="1672327" class="AnatomicStructure" value="Canal" score="1.00" ID="C61487">canal</Semaphore>) and distinct decrease in popliteal flow (left <Semaphore x="1930103" class="AnatomicStructure" value="Femoral Neck" score="1.00" ID="C61563">femora </Semaphore><Semaphore x="2951311" class="MedDRA LLT" value="Femoral arterial stenosis" score="1.00" ID="10016426">popliteal <Semaphore x="1841229" class="Disease or Finding" value="Dental Occlusion" score="1.00" ID="C62301">occlusion</Semaphore>), <Semaphore x="2584843" class="Disease or Finding" value="Stenosis" score="1.00" ID="C50754">stenosis </Semaphore></Semaphore>of the left <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372"><Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">femoral artery</Semaphore>, </Semaphore>stent insertion in the left <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">femoral artery</Semaphore>, episode of <Semaphore x="2603025" class="Disease or Finding" value="Tachycardia" score="1.00" ID="C38029">tachycardia </Semaphore>treated with <Semaphore x="168570" class="Medicine" value="Atenolol" score="0.49" ID="213117">atenolol</Semaphore>, second stent and left <Semaphore x="1653643" class="Procedure" value="Bypass" score="1.00" ID="C15723">bypass </Semaphore><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>(<Semaphore x="2199735" class="Race" value="Manzanita" score="1.00" ID="C44529">several </Semaphore>episodes of recurrent <Semaphore x="2584843" class="Disease or Finding" value="Stenosis" score="1.00" ID="C50754">stenosis</Semaphore>), triple left <Semaphore x="1930103" class="AnatomicStructure" value="Femoral Neck" score="1.00" ID="C61563">femoral </Semaphore><Semaphore x="1653643" class="Procedure" value="Bypass" score="1.00" ID="C15723">bypass </Semaphore><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>(medical history corresponds to cases PHHO2008FR05280 and PHHO2008FR05568) and <Semaphore x="1875899" class="Disease or Finding" value="Electrical Exposure" score="1.00" ID="C45407">current </Semaphore>condition <Semaphore x="2361135" class="Disease or Finding" value="Overweight" score="1.00" ID="C94250">overweight</Semaphore>. The patient concomitant medications were not reported. The patient received <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>(<Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib</Semaphore>) for an unspecified indication from 10 Oct 2006 to 19 Feb 2008 at a dose of 400 mg twice daily, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>was restarted from 10 Apr 2008 to 21 Oct 2010 at a dose of 400 mg twice daily, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>was restarted from 21 Oct 2010 at a decreased dose of 200 mg twice daily, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. On an unspecified date, after starting <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>, the patient experienced <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram </Semaphore>deflection, <Semaphore x="2521321" class="Disease or Finding" value="Sign" score="1.00" ID="C53458">signs </Semaphore>of an <Semaphore x="1552503" class="Disease or Finding" value="Asymptomatic" score="1.00" ID="C3833">asymptomatic </Semaphore>previous <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">cardiac </Semaphore>event on <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram </Semaphore>and subclinical <Semaphore x="2253052" class="Disease or Finding" value="Myocardial Infarction by ECG Finding" score="1.00" ID="C101589">myocardial infarction</Semaphore>. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1248114" class="Medicine" value="Tasigna" score="0.93" ID="282225">Tasigna </Semaphore>was discontinued due to the events on an unspecified date in Nov 2012 and was switched to <Semaphore x="1060862" class="Medicine" value="ponatinib" score="0.49" ID="229488">ponatinib </Semaphore>(unspecified <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer</Semaphore>). The events were assessed as serious (medically significant) by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician</Semaphore>. The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality of the events were not reported.</narrativeincludeclinical>
				<sendercomment>The event can be explained by the underlying medical history of hypertension, hypercholestrolemia and diabetes.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>